RadioTherapeutics Corporation (RTC) is a worldwide provider of products utilizing radiofrequency (RF) energy in medical applications. The company’s primary focus is on the design, manufacture, and marketing of RF ablation devices to heat, and thereby destroy, large volumes of tissue. RTC was the first RF ablation company to announce specific FDA clearance to market its RF system for the ablation of nonresectable (inoperable) liver lesions. In addition, the company's RF ablation systems can create clinically useful thermal lesions in other soft tissues, such as lung, breast, and kidney. Surgeons, radiologists, and gastroenterologists have used RTC’s devices in thousands of procedures worldwide to ablate primary and metastatic tissue.
Return to Search Results
Search for Another Company